



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Sotagliflozin

|                    |                                                                                                  |
|--------------------|--------------------------------------------------------------------------------------------------|
| Cat. No.:          | HY-15516                                                                                         |
| CAS No.:           | 1018899-04-1                                                                                     |
| Molecular Formula: | C <sub>21</sub> H <sub>25</sub> ClO <sub>5</sub> S                                               |
| Molecular Weight:  | 425                                                                                              |
| Target:            | SGLT                                                                                             |
| Pathway:           | Membrane Transporter/Ion Channel                                                                 |
| Storage:           | Powder    -20°C    3 years<br>4°C    2 years<br>In solvent   -80°C    2 years<br>-20°C    1 year |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (235.29 mM)  
 \* "≥" means soluble, but saturation unknown.

|                              | Solvent<br>Concentration | Mass | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|--------------------------|------|-----------|------------|------------|
|                              |                          |      |           |            |            |
| Preparing<br>Stock Solutions | 1 mM                     |      | 2.3529 mL | 11.7647 mL | 23.5294 mL |
|                              | 5 mM                     |      | 0.4706 mL | 2.3529 mL  | 4.7059 mL  |
|                              | 10 mM                    |      | 0.2353 mL | 1.1765 mL  | 2.3529 mL  |

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution

### BIOLOGICAL ACTIVITY

|                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description               | Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IC <sub>50</sub> & Target | SGLT1/2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| In Vitro                  | LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying |

SGLT1-mediated intestinal glucose absorption [1]. LX4211-treated mice and SGLT1<sup>-/-</sup> mice also had increased GLP-1 AUC values, decreased glucose-dependent insulinotropic polypeptide (GIP) AUC values, and decreased blood glucose excursions during the 6 hours after a challenge with oral glucose alone [2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Nat Cell Biol. 2021 Jul;23(7):733-744.
- Curr Biol. 2022 Feb 15;S0960-9822(22)00137-3.
- Mol Metab. 2019 Jan;19:1-12.
- Oncogene. 2021 Jun 21.
- iScience. 2023 Jun 27.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.

[2]. Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA